Stage Business development
Investor Trendlines Incubators Israel
CEO Gilad Hizkiyahu
The ClearRing device is based on unique pre-shaped nitinol implants and a dedicated delivery system. ClearRing’s implants, in the shape of an open ring, are placed inside the enlarged prostate tissue, avoiding any long-term contact with the urine (unlike stents) and expand the obstructed area.
ClearRing is inserted into the obstructed area through a cystoscope. In a very simple, short, minimally invasive procedure (usually performed on an outpatient basis), the urologist makes a circular incision in the prostate tissue and places the implant inside it. As the incision is superficial, tissue recovery is quick, with minimal risk of adverse events.
ClearRing is positioned to be the treatment of choice for patients with benign prostatic hyperplasia (BPH, enlarged prostate) who have tried drugs and want to avoid surgery. It presents the market with numerous advantages:
2 US patents granted; 1 EU granted; additional patents pending
Opportunity: Despite the drug therapies and surgical options available, the market continues to seek innovative treatments that will reduce adverse events, decrease hospitalization stay, and improve quality of life.
Gilad Hizkiyahu has a decade of experience in the MedTech sector leading project management, operations, marketing, sales and business development.
Gilad holds an MBA from the Ben-Gurion university of the Negev and a BSc in Aerospace engineering from the Technion - Israel Institute of Technology.
Robert Bash is well-established in the Israeli health technology industry. He was a partner in joint US-Israeli venture funds, and for the past 15 years, he has been actively involved in the management of early-stage companies, from development to commercialization and to exit. He has worked with multiple technologies across several clinical indications.
BPH, or enlarged prostate, is a noncancerous growth of the cells within the prostate gland. A common condition, BPH affects about 50% of men over the age of 50 and 80% over the age of 80. Symptoms include a weak or slow urinary stream, a feeling of incomplete bladder emptying, delay in starting urination, frequent urination, and urinary urgency.
Current treatment options have numerous shortcomings:
Despite the options available, the market continues to seek innovative treatments that will reduce adverse events, decrease hospitalization stay, and improve quality of life.
Each year, an estimated 38 million men in the United States and EU with BPH become symptomatic and seek medical attention; 25% have debilitating conditions that require active treatment. The caseload is only expected to rise with the increase in the aging population. An estimated 1.5 million BPH procedures will be performed in the United States and EU in 2012, resulting in a $1.5 billion market opportunity for ProArc Medical.